Seven Fleet Capital Management LP Makes New Investment in Pharvaris N.V. $PHVS

Seven Fleet Capital Management LP purchased a new stake in Pharvaris N.V. (NASDAQ:PHVS) in the 4th quarter, HoldingsChannel reports. The fund purchased 55,342 shares of the company’s stock, valued at approximately $1,536,000. Pharvaris accounts for approximately 1.2% of Seven Fleet Capital Management LP’s portfolio, making the stock its 12th biggest holding.

Several other institutional investors have also recently made changes to their positions in PHVS. General Atlantic L.P. boosted its position in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after purchasing an additional 500,000 shares in the last quarter. Foresite Capital Management IV LLC increased its position in Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after buying an additional 368,000 shares in the last quarter. venBio Partners LLC increased its position in Pharvaris by 8.2% in the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after buying an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. raised its stake in Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after buying an additional 425,000 shares during the period. Finally, Commodore Capital LP raised its stake in Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after buying an additional 507,043 shares during the period.

Insider Buying and Selling

In related news, CEO Berndt Modig sold 23,333 shares of the company’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $27.74, for a total transaction of $647,257.42. Following the completion of the sale, the chief executive officer owned 142,084 shares in the company, valued at approximately $3,941,410.16. This represents a 14.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.32, for a total value of $881,402.40. Following the completion of the sale, the director directly owned 355,167 shares of the company’s stock, valued at $10,768,663.44. The trade was a 7.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 214,909 shares of company stock valued at $6,421,745. 11.84% of the stock is currently owned by company insiders.

Pharvaris Stock Performance

Shares of NASDAQ PHVS opened at $32.80 on Friday. Pharvaris N.V. has a fifty-two week low of $16.72 and a fifty-two week high of $34.41. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of -10.31 and a beta of -2.35. The firm’s 50-day simple moving average is $29.91 and its 200 day simple moving average is $27.71.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, sell-side analysts predict that Pharvaris N.V. will post -3.22 EPS for the current year.

Analyst Ratings Changes

PHVS has been the subject of a number of research reports. Citizens Jmp reduced their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Wedbush increased their target price on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. HC Wainwright reissued a “buy” rating on shares of Pharvaris in a research report on Tuesday. Finally, Royal Bank Of Canada decreased their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.